Loganin is a naturally occuring iridoid glycoside with antioxidant hepatoprotective and neuroprotective effects as well as a COX-1 inhbitor with IC50 value of 355 M suppressing the formation of TNF- and diminishing the production of nitric oxide
CAS Number: 18524-94-2
Molecular Weight: 390.38
Chemical Name: methyl (1S,4aR,6R,7S,7aR)-6-hydroxy-7-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : ≥ 100 mg/mL (256.16 mM)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In SMN-deficient NSC34 cells, loganin increases cell viability, neurite length, and expressions of SMN, Gemin2, SMN-Gemin2 complex, p-Akt, p-GSK-3, p-CREB, BDNF and Bcl-2. Loganin attenuates H2O2-induced neuronal damage via suppressing MAPKs signals in SH-SY5Y cells. Loganin may directly promote the differentiation and inhibit the apoptosis of MC3T3-E1 cells and indirectly reduce bone resorption. Loganin could directly enhance the function of osteoblasts and elevate their survival rate, indirectly inhibit the function of osteoclastd and reduce the number of osteoclastd via RANKL from osteoblastd.
Loganin provides benefits to SMA (pinal muscular atrophy) therapeutics via improving SMN (survival motor neuron) restoration, muscle strength and body weight. In type 2 diabetes mice, loganin not only lowers blood glucose but also attenuates hyperglycemia-induced inflammation, oxidative stress and apoptosis. Loganin improves spatial memory in streptozotocin-induced diabetic rats and exhibits antiamnesic activity in scopolamine-treated mice via acetylcholinesterase inhibition.
- Bhakta HK, et al. Arch Pharm Res. 2016, 39(6):794-805.
- Tseng YT, et al. Pharmacol Res. 2016, 111:58-75.
- Li M, et al. Molecules. 2010, 15(10):7403-14.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.